Literature DB >> 29271328

Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population.

Feng Zang1, Ming Yue2, Yinan Yao1, Mei Liu1, Haozhi Fan1, Yue Feng3, Xueshan Xia3, Peng Huang1, Rongbin Yu1.   

Abstract

The high rate of chronic hepatitis C (CHC) was one of the key issues of global public health concern. Interferon (IFN)-λ relevant genes were in the antiviral treatment pathway, not only influenced hepatitis C virus (HCV) spontaneous clearance, but also affected the IFN-mediated viral clearance. The aim of this study was to identify the association of interleukin 28B (IL28B), myxovirus resistance A (MxA) gene polymorphisms with HCV spontaneous clearance and therapeutic response in Chinese CHC patients. IL28B and MxA gene genotypes were detected among 231 CHC carriers, 428 subjects with HCV spontaneous clearance and 662 CHC patients with pegylated IFN-α and ribavirin (pegIFN-α/RBV) treatment. Patients with MxA rs2071430 TT genotype were more likely to develop HCV infection chronicity (additive model: odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01-1.48, P = 0.042). IL28B rs1298075 variant genotypes (additive model: OR 0.58, 95% CI 0.34-0.98, P = 0.040) and MxA rs17000900 variant genotypes (additive model: OR 0.54, 95% CI 0.30-0.99, P = 0.048) were less likely to achieve a sustained virological response. The life table indicated that patients with IL28B rs1298075 AG genotype were slower to achieve a viral load 106 copies/ml (all P < 0.05). This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-α/RBV among Chinese CHC patients.

Entities:  

Keywords:  zzm321990 IL28Bzzm321990 ; zzm321990 MxAzzm321990 ; Chronic hepatitis C; spontaneous clearance; treatment response

Mesh:

Substances:

Year:  2017        PMID: 29271328      PMCID: PMC9134562          DOI: 10.1017/S0950268817002928

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  32 in total

1.  Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population.

Authors:  Wanyu Li; Yanfang Jiang; Qinglong Jin; Xiaodong Shi; Jinglan Jin; Yanhang Gao; Yu Pan; Hong Zhang; Jing Jiang; Junqi Niu
Journal:  Liver Int       Date:  2011-03-30       Impact factor: 5.828

2.  Guidelines and recommendations on the prevention and control of hepatitis C. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Commun Dis Rep       Date:  1995-07

3.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

Review 4.  IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.

Authors:  Hao Zheng; Man Li; Bing Chi; Xiao-xue Wu; Jia Wang; Dian-Wu Liu
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-03-10       Impact factor: 2.947

5.  [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].

Authors:  Alajos Pár; Gabriella Pár; István Tornai; Ferenc Szalay; Dalma Várszegi; Edit Fráter; Mária Papp; Gabriella Lengyel; János Fehér; Márta Varga; Judit Gervain; János Schuller; Zsuzsanna Nemes; Zoltán Péterfi; Anna Tusnádi; Béla Hunyady; Attila Haragh; Zsolt Szinku; László Pálinkás; Tímea Berki; Aron Vincze; Péter Kisfali; Béla Melegh
Journal:  Orv Hetil       Date:  2013-08-11       Impact factor: 0.540

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

7.  Nomenclature and numbering of the hepatitis C virus.

Authors:  Carla Kuiken; Peter Simmonds
Journal:  Methods Mol Biol       Date:  2009

8.  Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.

Authors:  Hongbo Chen; Yuanyuan Zhang; Peng Huang; Yin Xu; Jie Wang; Jing Su; Rongbin Yu
Journal:  J Biomed Res       Date:  2014-11

Review 9.  Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  Susan J Bersoff-Matcha; Kelly Cao; Mihaela Jason; Adebola Ajao; S Christopher Jones; Tamra Meyer; Allen Brinker
Journal:  Ann Intern Med       Date:  2017-04-25       Impact factor: 25.391

Review 10.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

View more
  1 in total

1.  IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population.

Authors:  Neelanjana Roy; Chandreswar Prasad; Anand Kumar; Krishnendu Mondol; Kajal Jain; Renu Yadav; Jyotish Kumar Jha; Neeti Nadda; Subrat Kumar Acharya; Baibaswata Nayak
Journal:  Virusdisease       Date:  2019-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.